Femasys Inc. has announced the execution of an Omnibus Amendment and Consent Agreement with its lenders, aimed at modifying the terms of existing securities. This agreement, dated March 19, 2026, follows the Securities Purchase Agreement established on November 3, 2025, under which the company issued Senior Secured Convertible Notes and various warrants to its lenders. The primary purpose of the amendment is to remove the Share Combination Event Adjustment from the Notes and Warrants, effective December 31, 2025. In exchange for these amendments, each lender will receive a Series D-1 warrant, allowing them to acquire shares of the company's common stock at an exercise price of $0.58. This strategic move is expected to enhance the company's financial flexibility and strengthen its capital structure. Additionally, the company reported a change in its board of directors, with Joshua Silverman resigning and Kenneth D. Eichenbaum being appointed as a new director. Eichenbaum brings extensive clinical and healthcare technology experience, which may benefit the company's strategic direction moving forward. The company continues to operate under the Nasdaq Capital Market and is classified as an emerging growth company.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.